SAB Biotherapeutics to report Q1 2026 financials and host earnings call on May 12.

SAB Biotherapeutics, a clinical-stage biopharmaceutical company, will release its first quarter 2026 financial results on May 12, 2026. The company will hold a conference call and webcast at 8:30 AM ET to discuss the results and provide updates on its development of SAB-142, a treatment for type 1 diabetes and autoimmune diseases. SAB BIO uses proprietary genetic engineering technology to produce human immunoglobulin G for immune disorders. Investors and interested parties can access the live call by registration, with a replay available on the company's website afterward.